Remyelination is a term for the re-generation of the nerve's myelin sheath, damaged in many diseases such as multiple sclerosis (MS) and the leukodystrophies. Remyelination is a subject of active medical research.
Through their pattern of firing, neurons influence the behavior of the cells that upon maturation will provide insulation of neuronal axons, according to a new study publishing 22 August in the open access journal PLOS Biology by Balint Nagy, Maria Kukley and colleagues at the University of Tübingen, Germany.
Multiple sclerosis is an autoimmune disease of the central nervous system that affects nearly 2.3 million people worldwide.
Researchers have identified a gene (CYFIP2) associated with binge eating. This finding represents one of the first examples of a genome-wide significant genetic factor to be identified for binge eating in model organisms or humans.
Physicians at Rush University Medical Center became the first in Illinois to inject AST-OPC1 (oligodendrocyte progenitor cells), an experimental treatment, into the damaged cervical spine of a recently paralyzed man as part of a multicenter clinical trial.
Demyelinating diseases, such as multiple sclerosis and leukodystrophy, are characterized by damage to the protective myelin sheath that surrounds the axons of neurons.
To me the most exciting aspect of pre-clinical imaging is its broad range, from very basic science up to applied science. You deal with a range of disciplines including biology, chemistry, physics, biochemistry, biophysics, cell biology and of course medicine, as the aim is the translation of research to humans.
Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committee has reviewed the initial safety data from all three patients in the first cohort and has recommended dose escalation to the second cohort.
An experimental drug originally identified in a National Cancer Institute library of chemical compounds as a potential therapy for brain and basal cell cancers improves the symptoms of mice with a form of the debilitating neurological disorder multiple sclerosis (MS), according to new research from NYU Langone Medical Center.
Researchers in Japan have revealed the molecular mechanism involved in the process of repair to damage of the myelin sheath. In vertebrates, axons extending from nerve cells are covered by insulating sheets called the myelin sheath, made with the cell membranes of oligodendrocytes, enabling fast electrical signaling through saltatory conduction.
New research published this week in Nature has found several drugs could lead to new treatment options for multiple sclerosis (MS), including two drugs that effectively treat MS at the source, in vivo. When administered at the peak of disease, these two drugs showed a striking reversal of disease severity.
Two drugs already on the market -- an antifungal and a steroid -- may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis.
Genzyme, a Sanofi company, announced today that new longer-term data on its relapsing multiple sclerosis treatments, Aubagio (teriflunomide) and Lemtrada (alemtuzumab), will be featured during the 67th annual meeting of the American Academy of Neurology being held in Washington, D.C. April 18-25.
Damage to myelin, the fatty insulator that enables communication between nerve cells, characterizes multiple sclerosis (MS) and other devastating neurological diseases.
Multiple sclerosis (MS), an autoimmune disease of the brain and spinal cord, affects about 2.3 million people worldwide (400,000 in the United States). Affecting more women than men, it can be seen at any age, although it is most commonly diagnosed between the ages of 20 and 40.
Asterias Biotherapeutics, Inc. announced today that the Company has signed a Notice of Grant Award (NGA) with the California Institute of Regenerative Medicine (CIRM), effective October 1, 2014.
Two studies recently published in Cell Transplantation reveal that cell transplantation may be an effective treatment for spinal cord injury (SCI), a major cause of disability and paralysis with no current restorative therapies.
A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal.
Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury.
Neuregulin 1 (NRG1) is a pleiotropic factor characterized by the existence of numerous isoforms arising from alternative splicing of exons that confer to the protein deeply different characteristics.